Frazier Life Sciences Management L.P. Reduces Holdings in Disc Medicine, Inc. $IRON

Frazier Life Sciences Management L.P. reduced its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,260,000 shares of the company’s stock after selling 178,534 shares during the quarter. Disc Medicine comprises approximately 2.7% of Frazier Life Sciences Management L.P.’s holdings, making the stock its 10th largest position. Frazier Life Sciences Management L.P.’s holdings in Disc Medicine were worth $100,057,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Kennedy Capital Management LLC raised its holdings in Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after acquiring an additional 296 shares during the last quarter. Eventide Asset Management LLC raised its holdings in Disc Medicine by 28.4% in the 4th quarter. Eventide Asset Management LLC now owns 395,392 shares of the company’s stock worth $31,398,000 after acquiring an additional 87,349 shares during the last quarter. Entropy Technologies LP purchased a new position in Disc Medicine in the 4th quarter worth approximately $346,000. FORA Capital LLC purchased a new position in Disc Medicine in the 4th quarter worth approximately $544,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Disc Medicine by 10.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 52,510 shares of the company’s stock worth $4,072,000 after acquiring an additional 4,933 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IRON. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Cantor Fitzgerald decreased their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. BMO Capital Markets decreased their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Finally, Truist Financial decreased their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 27th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.30.

Disc Medicine Trading Down 0.1%

NASDAQ:IRON opened at $67.99 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -10.27 and a beta of 0.93. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The business has a fifty day moving average price of $68.16 and a 200-day moving average price of $72.57.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Sell-side analysts forecast that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In other news, insider William Jacob Savage sold 5,731 shares of the company’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the sale, the insider directly owned 79,480 shares in the company, valued at $5,275,882.40. This represents a 6.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the completion of the sale, the chief financial officer owned 64,333 shares of the company’s stock, valued at $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,388 shares of company stock valued at $841,258 over the last 90 days. 3.76% of the stock is currently owned by company insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.